What Are the Best Healthcare Stocks to Buy Now? I Think It's Intuitive Surgical (ISRG) -- or, to Play It Safer, Medtronic (MDT)

Intuitive Surgical remains the market leader in robotic surgery with over 9,900 da Vinci systems installed across 72 countries and more than 16 million procedures; roughly 25% of revenue comes from system sales and the remainder from recurring services and supplies, and the stock trades at a forward P/E of ~59 (five‑year avg 56) after a 23% share pop on a strong earnings report. Medtronic is making inroads into robotics with a more attractive valuation (forward P/E ~18 vs five‑year avg 17), reported a solid quarter ending Oct. 24 (FY26 Q2), and yields ~2.8% on dividends, suggesting a lower‑risk entry for investors who prefer valuation and income while Intuitive remains a growth‑priced, long‑term hold.

Analysis

Market structure: Medtronic (MDT) is the near-term beneficiary of investor rotation toward lower-PE, income-generating medtech while Intuitive (ISRG) retains durable aftermarket pricing power that supports margins. Expect downward pressure on da Vinci system ASP growth as competition forces concessions, but recurring consumables create stickiness that blunts share losses — net effect: slower system revenue growth, persistent high gross margins on attach revenues. Cross-asset: ISRG’s high forward multiple makes it rate- and vol-sensitive (higher duration), so equity beta/IV should rise when real rates tick up; MDT’s 2.8% yield reduces equity-duration, marginally supporting credit spreads in BBB/IG medtech names.

Risk assessment: Tail risks include an adverse FDA/antitrust action, a major device recall, or a material Medicare reimbursement cut — each could wipe 20–40% off ISRG’s market cap in 12 months. Immediate (days) risk is sentiment-driven mean reversion; short-term (weeks–months) hinge on guidance updates and install cadence; long-term (2–5 years) depends on adoption curves and consumables penetration. Hidden dependencies: hospital capital budgets and leasing vs purchase models, and attach-rate sensitivity to procedure mix; watch OEM service footprint and distributor contracts as second-order determinants of revenue retention.

Trade implications: Favor defensive, cash-yielding exposure to MDT while hedging ISRG’s valuation multiple — rotate 1–4% portfolio allocation from growth robotics into diversified medtech to harvest yield and compress P/E risk. Use collars on ISRG to preserve exposure to long-term upside while selling near-term call premium; deploy relative-value pair trades (long MDT / short ISRG) to exploit the 3x+ P/E spread over a 6–12 month horizon. Options: buy 9–12 month ISRG put spreads (20–30% OTM) financed by selling 3-month calls (10–15% OTM) to cap downside cost.

Contrarian angles: Consensus underestimates how sticky consumable economics are — Intuitive may sustain higher-than-expected cash flows even with share loss, so a full short could be punished if procedure volume growth accelerates. The 23% pop could be overbought into earnings momentum; if ISRG softens <‑15% from current levels, put buying becomes cheaper and more attractive. Historical parallel: platform-price compression followed by aftermarket monetization (think implantable devices) suggests asymmetric downside protection exists for ISRG but limited near-term upside vs cyclical entrants.

Key Decisions for Investors

• Establish a 3% long position in MDT (ticker MDT) now, size to 4–5% if shares pull back 7–10% or forward P/E drops to ≤16; target 12-month total return 8–12%, set a hard stop-loss at -15%.
• Reduce ISRG exposure by 25–40% after the 23% run; for remaining position implement a 9–12 month collar by buying a 20% OTM put and selling a 10–15% OTM call to finance ~50–70% of cost, preserving long-term upside while limiting near-term drawdown.
• Initiate a dollar-neutral pair: long MDT 1.5% funded by short ISRG 1.5% (equal-dollar) for 6–12 months; unwind if the P/E spread narrows to half current differential or after 12 months, whichever comes first.
• Buy ISRG 9–12 month put spread (buy 25% OTM, sell 40% OTM) sized to protect 5–10% of portfolio value, financed by selling 1–3 month 10% OTM covered calls on existing ISRG holdings to collect premium and reduce cost.